Nanexa confirms continued positive results from a new preclinical study of NEX-22
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Nanexa AB today announced that a preclinical study of NEX-22 in minipigs confirms a long release profile of liraglutide, which was previously seen in rats. The data show that a release profile of NEX-22 can be obtained for at least 28 days, which was the duration of the pharmacokinetic study and the goal of the study.
During the summer, the company has developed an additional number of PharmaShell® formulations with NEX-22 and is now awaiting a complementary pharmacokinetic study of these in rats, to be able to select the final formulation for the clinical Phase 1 study in patients with type 2 diabetes. The company sees good opportunities to obtain a pharmacokinetic profile that meets the requirements to create a one-month depot.
The preclinical program is proceeding according to plan and preparations are underway for the clinical trial application for the Phase 1 study of NEX-22 in patients, which is planned to be submitted during the fall. The study is planned to start in early 2024 and will be conducted in collaboration with the contract research company (CRO) Profil, in Germany, which is highly specialized in early clinical studies in diabetes and obesity.
“I am very pleased with the progress of the project and look forward with pleasure to the continued work of creating a one-month depot of liraglutide. The last year's market development for GLP-1 analogues in type 2 diabetes and obesity is enormous and we believe that a depot formulation of liraglutide can have a major impact on the market and make it easier for patients to follow the prescription of their medicine. We feel very excited about the upcoming development work and the commercial opportunities we see that it can bring”, said David Westberg, CEO of Nanexa.